Woodline Partners Adds $63M in Edwards Lifesciences Corporation ($EW)
Key Points
- Woodline Partners changed its Edwards Lifesciences Corporation ($EW) stake by 65.15% last quarter, boosting to 1,768,176 shares worth $159.95 million.
- Wall Street's consensus rating on $EW is Buy and an average price target of $100.96.
- $EW last traded around $90.46.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Woodline Partners increased its position in Edwards Lifesciences Corporation ($EW) by 65.15% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,768,176 shares of Edwards Lifesciences Corporation after buying 697,542 shares during the quarter. Woodline Partners's holdings in Edwards Lifesciences Corporation were worth $159.95 million as of its most recent filing.
Edwards Lifesciences Corporation Stock Up 0.3%
Shares of Edwards Lifesciences Corporation ($EW) traded around $90.46 on Saturday, up 0.3% for the day.
Edwards Lifesciences Corporation Earnings
Analysts Set New Price Targets
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Get Edwards Lifesciences Corporation alerts
New 13F filings, insider trades, and analyst moves on $EW, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.